A major challenge in acute myeloid leukemia (AML) has been the identification of potentially rare and genetically heterogeneous neoplastic cell populations with the capacity of impacting tumor evolution and the acquisition of therapeutic resistance. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, discusses the utilization of a newly developed technology enabling targeted single-cell DNA sequencing; improving our understanding of how intratumor heterogeneity changes in the context of a targeted inhibitor, notably gilteritinib.

свернуть